A Study to Evaluate ALN-2232 in Participants With Obesity

Registered clinical trial record on ClinicalTrials.gov (NCT07463846). This describes a planned, ongoing, or completed study — it is NOT peer-reviewed results. Status: recruiting. Study type: interventional. Phase: Phase 1/Phase 2. Sponsor: Alnylam Pharmaceuticals. Conditions: Obesity. Interventions: ALN-2232, Placebo, Tirzepatide. Summary: The purpose of this study is to: * evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity Primary outcome measures: Part A: Frequency of Adverse Events (AEs); Part B: Percent Change from Baseline in Body Weight; Part C: Percent Change from Baseline in Body Weight. Eligibility: Inclusion Criteria: All Parts: * Has a body mass index (BMI) of ≥30 kg/m\^2 and \<40 kg/m\^2 * Has a hemoglobin A1c (HbA1c) \<6.5% Exclusion Criteria: All Parts: * Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results * Receiving therapies for chronic weight management or antidiabetic medications Note: other protocol defined inclusion/exclusion criteria apply